Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013;36(6):1775–6. https://doi.org/10.2337/dc13-0707.

Article  PubMed  PubMed Central  Google Scholar 

Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82. https://doi.org/10.1542/peds.2012-3494.

Article  PubMed  Google Scholar 

21CFR314.55. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.55.

Pediatric Research Equity Act. https://www.fda.gov/drugs/development-resources/pediatric-research-equity-act-prea#:~:text=PREA%20gives%20FDA%20the%20authority,pediatric%20labeling%20for%20the%20product.

Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637–46. https://doi.org/10.1056/NEJMoa1903822.

Article  CAS  PubMed  Google Scholar 

Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022;387(5):433–43. https://doi.org/10.1056/NEJMoa2204601.

Article  CAS  PubMed  Google Scholar 

Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Lancet Diabetes Endocrinol. 2023;11(3):169–81. https://doi.org/10.1016/S2213-8587(22)00387-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Supplemental NDAs 201280/S-027, 201281/S-035, 208026/S-024 Clinical Review. https://www.fda.gov/media/172628/download

Food and Drug Administration. E11A pediatric extrapolation. 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation.

Travis J, Rothmann M, Thomson A. Perspectives on informative Bayesian methods in pediatrics. J Biopharm Stat. 2023. https://doi.org/10.1080/10543406.2023.2170405.

Article  PubMed  Google Scholar 

Food and Drug Administration. E11(R1) addendum: clinical investigation of medicinal products in the pediatric population. 2018. https://www.fda.gov/media/101398/download.

ADAPP. Children and adolescents: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement 1):S258–81. https://doi.org/10.2337/dc24-S014.

Article  Google Scholar 

Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159–67.

Article  CAS  PubMed  Google Scholar 

Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American diabetes association. Diabetes Care. 2018;41(12):2648.

Article  CAS  PubMed  PubMed Central  Google Scholar 

VICTOZA product label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf

BYDUREON Product Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022200s036lbl.pdf

TRULICITY Product Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125469s063lbl.pdf

JARDIANCE Product Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf

FARXIGA Product Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf

INVOKANA Product Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204042s043lbl.pdf

BLA 125370/s-064 and BLA 761043/s-007 multi-disciplinary review and evaluation benlysta® (belimumab) for intravenous infusion in children 5 to 17 years of age with SLE. https://www.fda.gov/media/127912/download.

NDA multi-disciplinary review and evaluation . https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/214070Orig1s000TOC.cfm.

Wang Y, Tu W, Kim Y, Sinks S, He J, Cambon A, et al. Statistical methods for handling missing data to align with treatment policy strategy. Pharm Stat. 2023;22(4):650–70. https://doi.org/10.1002/pst.2299.

Article  PubMed  Google Scholar 

Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials (London, England). 2010;7(1):5–18. https://doi.org/10.1177/1740774509356002.

Article  Google Scholar 

Schmidli H, Gsteiger S, Roychoudhury S, O’Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014;70(4):1023–32. https://doi.org/10.1111/biom.12242.

Article  PubMed  Google Scholar 

Röver C, Friede T. Meta-analytic-predictive priors based on a single study. 2025. arXiv preprint arXiv:2505.15502.

Neuenschwander B, Weber S, Schmidli H, O’Hagan A. Predictively consistent prior effective sample sizes. Biometrics. 2020;76(2):578–87. https://doi.org/10.1111/biom.13252.

Article  PubMed  Google Scholar 

Wiesenfarth M, Calderazzo S. Quantification of prior impact in terms of effective current sample size. Biometrics. 2020;76(1):326–36. https://doi.org/10.1111/biom.13124.

Article  PubMed  Google Scholar 

Morita S, Thall PF, Müller P. Determining the effective sample size of a parametric prior. Biometrics. 2008;64(2):595–602. https://doi.org/10.1111/j.1541-0420.2007.00888.x.

Article  PubMed  Google Scholar 

Zhang H, Anderson KM, Zimmer Z, Golm G, Sapre A, Ibrahim JG.. Prior Effective sample size when borrowing on the treatment effect scale. 2024. arXiv preprint arXiv:2404.13366.

JANUMET Product Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022044s052lbl.pdf

JANUMET XR Product Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202270s026lbl.pdf

Schmidli H, Häring DA, Thomas M, Cassidy A, Weber S, Bretz F. Beyond randomized clinical trials: use of external controls. Clin Pharmacol Ther. 2020;107(4):806–16. https://doi.org/10.1002/cpt.1723.

Article  PubMed  Google Scholar 

Majumdar A, Rothwell R, Reaman G, Ahlberg C, Roy P. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: a pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL). J Biopharm Stat. 2023. https://doi.org/10.1080/10543406.2022.2162069.

Article  PubMed  Google Scholar 

Sebastien B, Cheung SA, Corriol-Rohou S, Gamalo-Siebers M, Jreich R, Krishna R, et al. Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials. J Biopharm Stat. 2022. https://doi.org/10.1080/10543406.2022.2149772.

Article  PubMed  Google Scholar